Quick Facts (Therapeutic Domains)

• Gastroesophageal Reflux Disease (GERD): May help address symptoms such as heartburn and acid regurgitation.
• Ulcers: Used to support the management of ulcers in the stomach (gastric) and the upper part of the intestine (duodenal).
• H. pylori: Utilized as part of combination therapy to address ulcers associated with Helicobacter pylori bacterial infection.
• Hypersecretory Conditions: May be considered for conditions linked to excessive stomach acid production, such as Zollinger-Ellison syndrome.

---

Omeprazol Cinfa is a prescription and over-the-counter medicine used to manage conditions related to excess stomach acid. The compound may be used to help with the symptoms associated with Gastroesophageal Reflux Disease (GERD), including heartburn and acid regurgitation, in both adults and certain pediatric groups. It may also support the healing of damage to the esophagus caused by acid reflux.

The medication is indicated for the treatment of duodenal and gastric ulcers. In specific situations, it is combined with other medications to address ulcers linked to the H. pylori bacterium. Furthermore, Omeprazol Cinfa may be used as a measure to help prevent the formation of ulcers in patients requiring treatment with certain non-steroidal anti-inflammatory drugs (NSAIDs).

The compound may also be utilized to help manage rare conditions that result in the stomach producing unusually high amounts of acid, such as Zollinger-Ellison syndrome.

Regulatory References

1. NIH MedlinePlus guidance

Official Eligibility Profile for Omeprazol Cinfa

Eligibility to use Omeprazol Cinfa is strictly defined by regulatory documents, focusing on patient population, age, and pre-existing conditions.

Absolute Non-Eligibility (Contraindications)

Omeprazol Cinfa must not be used by individuals with a known hypersensitivity to omeprazole, any substituted benzimidazoles, or any component of the formulation. Use is also contraindicated if the patient is simultaneously taking the antiretroviral medication nelfinavir or rilpivirine.

Age-Specific Eligibility

Age Group	Eligibility Status
Adults	Generally eligible for labeled uses.
Children	Approved for specific uses (e.g., GERD) for those over 1 year of age and ge 10 kg.
OTC Use	Restricted to individuals 18 years of age and older.

Conditional Use and Restrictions

Use in patients with impaired hepatic function is conditional; while not prohibited, a reduced daily dose may be necessary due to altered drug metabolism. Use in pregnant women should be determined by a medical professional after weighing the benefits against potential risks. It is often not recommended for women who are breastfeeding due to limited safety data.

Interactions with other medicines and products

Omeprazol Cinfa's interaction profile, documented in regulatory sources, is defined by its effects on gastric acidity and its role as an inhibitor of the CYP2C19 enzyme.

Formal Restrictions and Contraindications

Co-administration with Rilpivirine-containing products is formally contraindicated due to the significant risk of reducing rilpivirine plasma concentrations. Regulatory documents also state that concomitant use with the antiplatelet agent Clopidogrel should be avoided. This restriction is based on Omeprazole's effect of inhibiting the CYP2C19 enzyme, which leads to diminished anti-platelet activity.

Pharmacokinetic and Exposure Alterations

Mechanism/Domain	Outcome on Co-administered Drug
Alteration of Gastric pH	Decreased absorption for pH-sensitive drugs like Atazanavir, Nelfinavir, and certain antifungals, making concomitant use not recommended in some cases.
	Increased exposure for drugs such as Digoxin and Saquinavir.
CYP2C19 Inhibition	Increased systemic exposure and reduced clearance of substrates like Diazepam, Cilostazol, and Warfarin (requiring INR monitoring).

Product and Procedural Constraints

St John's Wort and Rifampin may reduce Omeprazole concentrations, and co-administration should be avoided. A procedural constraint requires that Omeprazole be stopped at least 14 days before measuring Chromogranin A (, CgA,) levels, as its effect on gastric pH interferes with the accuracy of this diagnostic test.

Irreversible Blockade of the Proton Pump

Omeprazol Cinfa's function centers on its specific, irreversible inhibition of the enzyme responsible for gastric acid production. The drug acts as a prodrug that is activated exclusively within the highly acidic environment of the stomach's parietal cells. Once activated, the compound targets the H^+/K^+-ATPase (Proton Pump) enzyme, which is the final step for releasing acid ( H^+ ions) into the stomach lumen. The activated drug forms a covalent bond with this enzyme , which interrupts the final step of the acid secretion pathway regardless of upstream physiological stimuli.

---

Sustained Suppression of Acid Secretion

This irreversible inhibition creates a significant and sustained elevation of intragastric pH (reduction of acidity). The duration of this physiological effect is not dictated by drug concentration in the blood, but rather by the cell’s natural rate of synthesizing new, functional proton pump enzymes. This synthesis-dependent restoration mechanism governs the prolonged physiological effect, which typically lasts 18 to 24 hours. The drug exerts its greatest effect on pumps that are actively secreting acid, requiring parietal cell stimulation for maximal inhibition.

Official Administration Guidelines for Omeprazol Cinfa

The usage of Omeprazol Cinfa is governed by detailed instructions to ensure the proper delivery of the active substance, omeprazole, a delayed-release formulation. The primary approved route of administration is oral, typically as a capsule or tablet, though an intravenous (IV) infusion is available for patients unable to take the medicine by mouth.

Dosing and Schedule Patterns

Omeprazole is usually taken once daily, preferably before a meal in the morning. Standard adult dosing for initial treatments, such as duodenal ulcer or erosive esophagitis, is often 20 mg to 40 mg once daily, typically continuing for a fixed course of four to eight weeks. For conditions requiring high-dose administration, such as Zollinger-Ellison syndrome, the starting dose is often 60 mg once daily. Any total daily dosage exceeding 80 mg is typically divided and administered twice daily.

Administration Instructions

The capsule or tablet is intended to be swallowed whole with water. The integrity of the delayed-release coating is essential; therefore, the medication is not to be crushed, chewed, or opened, as this allows stomach acid to inactivate the contents. If a dose is missed, standard protocol is to take it as soon as possible unless it is within 12 hours of the next scheduled dose, in which case the missed dose is skipped to avoid taking a double dose. Pediatric dosing is determined by body weight, and for patients with severe hepatic impairment, a lower daily dose of 10 mg to 20 mg may be sufficient.

Research Evidence / Overview of Studies for Omeprazol Cinfa

This section provides a summary of the research structure for Omeprazole (Omeprazol Cinfa), describing the types of trials performed, the research questions that were explored, and the patterns that were reported in the findings, based on official regulatory and scientific literature.

---

Evidence for Use in Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis

Omeprazol was evaluated in a significant number of Randomized Controlled Trials (RCTs) and Systematic Reviews for conditions such as GERD and Erosive Esophagitis. These studies primarily included adults, with separate research conducted for children (ages 1–16) and infants (1 month to 1 year).

Researchers in these trials explored outcomes related to inflammatory or irritative states, such as measuring the rate at which tissue damage in the esophagus healed (endoscopic healing rates). They also applied in studies examining patient-reported experiences, tracking changes in outcomes related to physical discomfort like heartburn and acid regurgitation over time. For most adult populations, the findings describe patterns observed in the studies concerning tissue healing after defined short-term treatment intervals.

---

Evidence for Use in Duodenal and Gastric Ulcers

The research for Omeprazol was studied for conditions involving ulcers in the stomach and the upper intestine. The evidence relies on Short-term RCTs and Comparative Trials that examined acute ulcer treatment.

Data show patterns related to research examining the formation of new ulcers in patients who were concurrently taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This indicates that studies explored short-term symptom changes and healing rates in these specific cohorts.

---

Evidence in Special Populations and Uncertainties

Omeprazol was evaluated in pediatric cohorts for acid reflux. However, the data for certain groups remain insufficient, and the sample sizes were modest in many pediatric trials. In these specific studies, findings were mixed regarding outcomes related to physical discomfort (symptoms), with some results showing patterns that were similar to placebo.

Long-term effects are not fully established or well-characterized, particularly regarding follow-up beyond one to two years for all approved indications. Comparative evidence is lacking for many direct, head-to-head comparisons against the newest PPI compounds. Findings describe group patterns, not personal outcomes; research provides context but not individual predictions.

Common questions about Omeprazol Cinfa (FAQ)

Q: Can Omeprazol Cinfa be used to treat H. pylori infection?

Official product labeling indicates that Omeprazole has an approved use for treating certain infections. The drug is indicated, in combination with antibiotics, for the eradication of Helicobacter pylori to help reduce the risk of recurrent duodenal ulcers. This information reflects the stated conditions for use found in regulatory documents.

---

Q: How long does the acid-blocking effect of one dose last?

Studies included in regulatory documents show that the anti-secretory effect, which blocks acid production, begins within approximately one hour after a dose, with the maximal effect occurring within two hours. The physiological duration of the acid-blocking activity is sustained, and inhibition may last for up to 72 hours. This prolonged effect is dependent on the natural process of forming new acid-producing pumps.

---

Q: What should I know about using this drug during pregnancy or breastfeeding?

Regarding breastfeeding, official product information states that Omeprazole is present in breast milk. However, it is generally considered unlikely to influence the child when therapeutic doses are used. Consultation with a healthcare professional is necessary for decisions regarding use during pregnancy and while breastfeeding.

---

Q: Does Omeprazol Cinfa come in a liquid formulation for children?

Official drug information confirms that Omeprazole is available in multiple forms, as listed in the product's regulatory documents. Formulations such as a powder for oral suspension are made available for patients who may have difficulty swallowing the solid dosage forms.

Official Storage and Disposal Requirements

The storage of Omeprazol Cinfa must adhere strictly to labeled conditions to ensure product integrity. The medicine must be stored below 25^circC to maintain stability.

Protection and Handling

• Packaging: Keep the product in its original container or blister and protected from moisture. If provided in a bottle, the container should remain tightly closed.
• Safety: The medication must be kept out of the sight and reach of children as a mandatory safety requirement.

Disposal Instructions

Unused or expired Omeprazol Cinfa must not be disposed of via household waste or wastewater. Patients should consult a pharmacist for guidance on proper disposal, as discarding the medicine according to local regulations helps protect the environment. This procedure is required for pharmaceutical waste management.